Show simple item record

dc.contributor.authorYan, Lufeng
dc.contributor.authorSong, Yuefan
dc.contributor.authorXia, Ke
dc.contributor.authorHe, Peng
dc.contributor.authorZhang, Fuming
dc.contributor.authorChen, Shiguo
dc.contributor.authorPouliot, Robert
dc.contributor.authorWeiss, Daniel J.
dc.contributor.authorTandon, Ritesh
dc.contributor.authorBates, John T.
dc.contributor.authorEderer, Dallas R.
dc.contributor.authorMitra, Dipanwita
dc.contributor.authorSharma, Poonam
dc.contributor.authorDavis, April
dc.contributor.authorLinhardt, Robert J.
dc.date2021
dc.date.accessioned2022-06-27T15:36:58Z
dc.date.available2022-06-27T15:36:58Z
dc.date.issued2021-05-15
dc.identifier.citationHeparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus, L. Yan, Y. Song, K. Xia, P. He, F. Zhang, S. Chen, Ro. Pouliot, D. J. Weiss, R. Tandon, J. T. Bates, D. R. Ederer, D. Mitra, P. Sharma, A. Davis, R. J. Linhardt, Carbohydrate Polymers, 260, 117797, 2021.
dc.identifier.issn1448617
dc.identifier.urihttps://doi.org/10.1016/j.carbpol.2021.117797
dc.identifier.urihttps://hdl.handle.net/20.500.13015/5459
dc.descriptionCarbohydrate Polymers, 260, 117797
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractSevere acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has resulted in a pandemic and continues to spread at an unprecedented rate around the world. Although a vaccine has recently been approved, there are currently few effective therapeutics to fight its associated disease in humans, COVID-19. SARS-CoV-2 and the related severe acute respiratory syndrome (SARS-CoV-1), and Middle East respiratory syndrome (MERS-CoV) result from zoonotic respiratory viruses that have bats as the primary host and an as yet unknown secondary host. While each of these viruses has different protein-based cell-surface receptors, each rely on the glycosaminoglycan, heparan sulfate as a co-receptor. In this study we compare, for the first time, differences and similarities in the structure of heparan sulfate in human and bat lungs. Furthermore, we show that the spike glycoprotein of COVID-19 binds 3.5 times stronger to human lung heparan sulfate than bat lung heparan sulfate.
dc.description.sponsorshipNational Institutes of Health
dc.languageen_US
dc.language.isoENG
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofCarbohydrate Polymers
dc.relation.urihttps://harc.rpi.edu/
dc.subjectBiology
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleHeparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus
dc.typeArticle
dcterms.isPartOfJournal
dcterms.isVersionOfhttps://doi.org/10.1016/j.carbpol.2021.117797
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
dc.creator.identifierhttps://orcid.org/0000-0003-2219-5833
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
rpi.description.volume260


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record